PCM
IMGN

Prelude Capital Management’s Immunogen Inc IMGN Stock Holding History

Prelude Capital Management’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-157,856
Closed -$4.68M – 1584
2023
Q4 		$4.68M Buy
157,856
+56,541
+56% +$1.13M 0.31% 58
2023
Q3 		$1.61M Buy
101,315
+24,933
+33% +$415K 0.1% 226
2023
Q2 		$1.44M Buy
+76,382
New +$902K 0.09% 249
2019
Q3 		– Sell
-3,175
Closed -$7K – 2164
2019
Q2 		$7K Buy
+3,175
New +$7.51K ﹤0.01% 1474
2018
Q2 		– Sell
-2,200
Closed -$23K – 2013
2018
Q1 		$23K Buy
+2,200
New +$21.7K ﹤0.01% 1242
2017
Q4 		– Sell
-4,500
Closed -$34K – 1796
2017
Q3 		$34K Buy
+4,500
New +$29.9K ﹤0.01% 1204
2016
Q4 		– Sell
-12,700
Closed -$34K – 1840
2016
Q3 		$34K Buy
12,700
+7,050
+125% +$20.5K ﹤0.01% 1182
2016
Q2 		$17K Sell
5,650
-4,150
-42% -$26K ﹤0.01% 1326
2016
Q1 		$83K Buy
9,800
+4,500
+85% +$38.1K 0.01% 820
2015
Q4 		$72K Hold
5,300
– – 0.01% 937
2015
Q3 		$51K Sell
5,300
-600
-10% -$8.77K 0.01% 1056
2015
Q2 		$85K Sell
5,900
-600
-9% -$6.59K 0.01% 940
2015
Q1 		$58K Sell
6,500
-8,000
-55% -$57.9K 0.01% 1226
2014
Q4 		$88K Buy
+14,500
New +$133K 0.01% 1054
2014
Q2 		– Sell
-38,823
Closed -$580K – 2226
2014
Q1 		$580K Buy
38,823
+25,675
+195% +$405K 0.08% 342
2013
Q4 		$193K Hold
13,148
– – 0.03% 631
2013
Q3 		$224K Sell
13,148
-19,852
-60% -$349K 0.04% 506
2013
Q2 		$547K Buy
+33,000
New +$535K 0.12% 233

Other funds holding IMGN

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Prelude Capital Management's IMGN Position: Q1 2024 in Review

Prelude Capital Management sold out of Immunogen Inc (IMGN) in Q1 2024, closing a stake of 157,856 shares — an estimated $4.68M sold.

Prelude Capital Management first reported a position in IMGN in Q2 2013 and held it in 18 quarters. The position peaked at $4.68M in Q4 2023. 3 funds tracked by Wall St. Rank hold IMGN as of Q1 2024.

  • Prelude Capital Management reported no remaining Immunogen Inc position as of Q1 2024 after selling out during the quarter.
  • Prelude Capital Management sold 157,856 Immunogen Inc shares in Q1 2024, an estimated $4.68M.
  • Prelude Capital Management first reported a position in Immunogen Inc in Q2 2013 and held it in 18 quarters.
  • Prelude Capital Management's Immunogen Inc position peaked at $4.68M in Q4 2023.
  • 3 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2024.

Based on Prelude Capital Management's 13F filing for Q1 2024, filed 15 May 2024.